Vol. 7, Issue 1, Part A (2025)

The incidence of Gastroesophageal reflux disease (GERD) is on the rise in India owing to lifestyle and food habit changes. GERD poses special diagnostic and therapeutic challenges. Proton pump inhibitors (PPIs) are traditionally first-line therapies, but PPIs are associated with a variety of limitations, like the need to take before a meal, action on active proton pumps only, prodrug status, longer time needed for producing a full effect, short half-life, pharmacokinetics getting affected by genetic polymorphism, etc. Emerging therapies like potassium-competitive acid blockers (P-CABs), like Vonoprazan, have overcome many limitations of PPIs. Vonoprazan is now approved in many countries and has also been featured in some guidelines. Vonoprazan's effectiveness, once daily dose, full effect after the first dose, and flexible dosing without regard to meals make it a viable alternative for PPI. The comparative safety data of Vonoprazan shows promising results, with ongoing studies investigating long-term effects. Vonoprazan represents a paradigm shift in acid inhibition therapy, offering promise for improved management of GERD